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Declining Intensive Care Unit Mortality of COVID-19: A
Multi-Center Study
Sohaib Roomia, g, Syed Omar Shahb, Waqas Ullaha, Shan Ul Abedina, Karyn Butlerc,
Kelly Schiersd, Benjamin Kohle, Erika Yoof, Matthew Vibbertb, Jack Jallob

Abstract
Background: Coronavirus disease 2019 (COVID-19) mortality has
waned significantly over time; however, factors contributing towards
this reduction largely remain unidentified. The purpose of this study
was to evaluate the trend in mortality at our large tertiary academic
health system and factors contributing to this trend.
Methods: This is a retrospective cohort study of intensive care unit
(ICU) patients diagnosed with COVID-19 between March and August 2020 admitted across 14 hospitals in the Philadelphia area. Collected data included demographics, comorbidities, admission risk of
mortality score, laboratory values, medical interventions, survival
outcomes, hospital and ICU length of stay (LOS) and discharge
disposition. Chi-square (χ2) test, Fisher exact test, Cochran-MantelHaenszel method, multinomial logistic regression models, independent sample t-test, Mann-Whitney U test and one-way analysis of variance (ANOVA) were used.
Results: A total of 1,204 patients were included. Overall mortality
was 39%. Mortality declined significantly from 46% in March to 14%
in August 2020 (P < 0.05). The most common underlying comorbidities were hypertension (60.2%), diabetes mellitus (44.7%), dyslipidemia (31.6%) and congestive heart failure (14.7%). Hydroxychloroquine (HCQ) use was more commonly associated with the patients
who died, while the use of remdesivir, tocilizumab, steroids and duration of these medications were not significantly different. Peak values
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of ferritin, lactate dehydrogenase (LDH), C-reactive protein (CRP)
and D-dimer levels were significantly higher in patients who died (P <
0.05). The mean hospital LOS was significantly longer in the patients
who survived compared to the patients who died (18 vs. 12, P < 0.05).
Conclusions: The mortality of patients admitted to our ICU system
significantly decreased over time. Factors that may have contributed to this may be the result of a better understanding of COVID-19
pathophysiology and treatments. Further research is needed to elucidate the factors contributing to a reduction in the mortality rate for
this patient population.
Keywords: COVID-19; SARS-CoV-2; Mortality; Intensive care unit

Introduction
Coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) spread
across the globe in a matter of months. On March 11, 2020,
the World Health Organization (WHO) labeled it as a pandemic and issued emergency use authorization (EUA) for various drugs to counter the devastation caused by this “once in a
century pandemic” [1]. Various off-label and compassionate
use drugs have been trialed based on in vitro activity against
SARS-CoV-2. Efficacy has been limited except for low-dose
dexamethasone and remdesivir as per preliminary data of the
Recovery trial [2, 3]. By the end of August 2020, more than 30
million cases have been reported worldwide, 6.5 million cases
in the USA and a total death toll of around 200,000 in the USA.
Although the total number of cases is increasing over
time, recent data from Europe suggest that the mortality rate
from COVID-19 has declined in all age groups, and the older
age groups drive the overall reduction. In Germany, the case
fatality rate declined from 29% in mid-April to 11% by the end
of July in patients aged 80 and above, while a sharper decline
from 9% in March to 2% in July was observed in the age group
between 60 and 79 years [4]. However, the intensive care unit
(ICU) mortality rate varies significantly between countries and
over time, which renders it to be highly uncertain. A recent
study from Emory University reported an ICU mortality rate of
30.9% at the end of April 2020, which was significantly lower
compared to earlier mortality rates of 50-70% as per previous
reports from China, Italy and Seattle [5].
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The primary outcome of this study was to evaluate the
trend in COVID-19 mortality at our large academic health system consisting of 14 hospitals serving the greater Philadelphia
area and southern New Jersey. Secondary outcomes evaluated
differences in demographics, comorbidities, ICU interventions
and outcomes of the patients who survived compared to patients who died during the study period.

Materials and Methods
Study design and participants
This is a retrospective cohort study of all patients with confirmed COVID-19 infection who were admitted to the ICUs
across 14 affiliated hospitals of the Jefferson Health System
between March 1, 2020, and August 31, 2020. Jefferson Health
is a multi-state non-profit health system with its main hospital
located in Center City, Philadelphia. With its affiliate hospitals, the system serves the population of the greater Philadelphia area and southern New Jersey. During the study period,
all patients admitted to the ICU were cared for by a dedicated
critical care team with standard ICU staffing ratios. There was
no shortage of medications or critical care equipment during
the study period. The Institutional Review Board approved this
study and the Research Ethics Committee waived the requirement for informed consent.
Data collection
Data were extracted from electronic medical records (Epic,
Verona WI and Sunrise, Chicago, IL) using a standardized
data collection form by our data analytics team. Collected
data included patient demographics (age, gender, ethnicity),
comorbidities (diabetes mellitus, hypertension, dyslipidemia,
heart failure, smoking, chronic obstructive pulmonary disease,
asthma, atrial fibrillation, chronic kidney disease, and stroke),
medications (hydroxychloroquine (HCQ), tocilizumab (TCZ),
remdesivir, steroids), respiratory support (mechanical intervention, bilevel positive airway pressure (BiPAP), high-flow
nasal cannula (HFNC)), and adjunctive interventions (extracorporeal membrane oxygenation (ECMO), epoprostenol
sodium, nitric oxide). Laboratory values (C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), D-dimer, ferritin, fibrinogen, lactate dehydrogenase (LDH) were collected
on admission, day 1, day 10 and peak values during the hospital stay (highest lab values irrespective of the day of hospitalization). Admission risk of mortality score was determined
using software developed by Vizient Inc. (Irving, Texas) and
was classified as minor, moderate, major, and extreme. Patient
outcomes and length of stay (LOS) were also collected. Realtime polymerase chain reaction (RT-qPCR) was used to detect the virus in nasopharyngeal, tracheal, or other respiratory
specimens; and patients were considered to have confirmed
infection if the initial or repeat test was positive. For patients
with readmission during the study period, data from the first
admission were used.

Statistical analysis
A Chi-square (χ2) test was used for comparison of categorical
data and Fisher exact test was adopted if the expected count
in more than 20% cells was less than 5. Continuous variables
were presented as means and standard deviations, while categorical variables were reported in percentages and proportions.
To quantify the association between the dichotomous categorical variables, an unadjusted odds ratio (uOR) was obtained using a Cochran-Mantel-Haenszel method. Multinomial regression analysis was used to adjust our outcome for all variables
collected. For normally and abnormally distributed continuous data, an independent sample t-test and Mann-Whitney U
test were used, respectively. A one-way analysis of variance
(ANOVA) was used to compare differences in the mean of
continuous variables for multiple in-hospital complications. A
two-sided α < 0.05 was considered statistically significant with
corroborating inference from a 95% confidence interval (CI).
Statistical analyses were performed using the SPSS software
(version 25, IBM Corp).

Results
Demographics and baseline characteristics
A total of 1,204 patients were admitted to the ICU with
confirmed SARS-CoV-2 infection. There were 715 males
(59.3%), and a majority of patients were white (51.6%). The
mean age in years for the alive and dead was 62 and 70 years,
respectively (P < 0.05). Besides age, there was no statistically
significant difference between those who survived compared
to the ones who died in terms of demographics and coexisting comorbidities (Table 1). The most common underlying
comorbidities were hypertension (60.2%), diabetes mellitus
(44.7%), dyslipidemia (31.6%) and congestive heart failure
(14.7%) in both the comparison groups. A significantly higher number of patients who died had a risk of mortality score
categorized as extreme compared to the people who lived
(96% vs. 70%, P < 0.05). ESR on admission was significantly
higher among the patients who died (P < 0.05), while CRP,
LDH, ferritin and fibrinogen were not significantly different
between the two groups (P = 0.36, P = 0.09, P = 0.29, and
P = 0.41, respectively). Comorbidities and the use of steroids, HCQ, TCZ or remdesivir during hospitalization were
not significantly different between those who survived and
those who died.
Mortality
The overall mortality was 39%. Mortality declined significantly over time from 46% in March to 14% in August 2020 with
a statistically significant difference between the months. For
head-to-head comparison between individual months, we used
August as a reference, and mortality of each individual month
was compared against it. The adjusted odds of mortality were
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Table 1. Demographic Information, Baseline Comorbidities and Admission Laboratory Values
Parameters

All (n)

Alive n (%)

Dead n (%)

P value

N

1,204

734 (61)

470 (39)

< 0.05

Age (mean)

66

62

70

< 0.05

  Male

715

433 (59)

282 (60)

0.73

  Female

489

301 (41)

188 (40)

  White

622

380 (52)

242 (52)

   African American

418

248 (34)

170 (36)

  Hispanic

32

24 (3)

8 (2)

  Asian

99

63 (9)

36 (8)

  Unknown

32

18 (3)

14 (3)

BMI (mean)

32

32

32

0.87

HTN

725

434 (59)

291 (62)

0.34

Dyslipidemia

381

235 (32)

146 (31)

0.73

Diabetes

539

320 (44)

219 (47)

0.31

COPD

26

13 (2)

13 (3)

0.25

CKD

129

72 (10)

57 (12)

0.21

CHF

177

117 (16)

60 (13)

0.13

Smoking

192

126 (17)

66 (14)

0.15

Asthma

122

83 (11)

39 (8)

0.09

Atrial fibrillation

128

79 (11)

49 (10)

0.85

  Minor

3

3 (0.4)

0 (0)

< 0.05

  Moderate

30

30 (4)

0 (0)

  Major

169

154 (21)

15 (3)

  Extreme

964

515 (70)

449 (95)

  Not available

38

32 (4)

6 (1)

  CRP, mg/L

13.2

12.7

13.8

0.36

  D-dimer, ng/mL

2,101

1,902

2,296

0.40

  ESR, mm/h

5912

4483

7342

< 0.05

  Ferritin, mg/L

1,472

1,323

1,620

0.29

  Fibrinogen, mg/dL

623

632

614

0.41

  LDH, U/L

482

545

420

0.09

  Sex

Race
0.45

Admission mortality risk score

Mean labs value on day 1

BMI: body mass index; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; CHF: congestive heart
failure; N: number; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase.

significantly lower in August as compared to March, April and
May (P < 0.05, Table 2).
Intervention and outcomes
Compared to those who survived, patients who died in the ICU
were more likely to require invasive mechanical ventilation
186

(79% vs. 46%, P < 0.05), BiPAP (40% vs. 29%, P < 0.05) or
epoprostenol sodium (15% vs. 3.4%, P < 0.05, Table 3). The
use of inhaled pulmonary vasodilators was relatively uncommon (0.16%) and 27 patients (2.24%) received ECMO. Use of
HCQ was more commonly associated with the patients who
died compared to the patients who survived (56% vs. 44%, P <
0.05), while the use of remdesivir, TCZ, steroids and duration
of these medications were not significantly different between
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Table 2. Crude and Adjusted Mortality Trend by Month
Month

Admissions (n)

Mortality (%)

P value

AOR (95% CI)

P value

March

142

46

< 0.05

16.81 (3.59 - 78.78)

< 0.05

April

530

46

10.25 (2.58 - 40.79)

< 0.05

May

290

38

5.59 (1.48 - 21.14)

< 0.05

June

105

25

3.46 (.793 - 15.13)

0.09

July

88

23

2.73 (0.64 - 11.58)

0.18

August

49

14

Total

1,204

39

Reference group
< 0.05

Factors that were adjusted for mortality trend by month included patients’ age, gender, ethnicity, comorbidities (diabetes mellitus, hypertension, dyslipidemia, heart failure, smoking, chronic obstructive pulmonary disease, asthma, atrial fibrillation, chronic kidney disease, and stroke), medications
(hydroxychloroquine, tocilizumab, remdesivir, steroids), admission laboratory values (CRP, ESR, D-dimer, ferritin, fibrinogen, lactate dehydrogenase)
and admission risk of mortality score. AOR: adjusted odds ratio; CI: confidence interval; CRP: C-reactive protein; ESR: erythrocyte sedimentation
rate.

the two groups. Compared to the patients who survived, the
peak values of ferritin, LDH, CRP and D-dimer level were significantly higher in patients who died (Supplementary Material 1, www.jocmr.org). The average hospital LOS was longer
in the patients who lived compared to the patients who died
at the end of hospitalization (18 vs. 12, P < 0.05). Majority of
the patients who survived were discharged to either inpatient
rehabilitation (42%) or skilled nursing facilities (30%).

Discussion
Our experience with critically ill COVID-19 patients showed
an overall mortality lower than previous reports [5]. More
importantly, we noticed a significant improvement in mortality rates over time, and this difference in mortality remained
significant even after adjusting for demographics, underlying
comorbidities, risk of mortality index, medications and other
interventions employed during the ICU stay.
Odds of mortality were significantly higher in older patients and those with higher ESR levels on admission. Higher
peak values of ferritin, LDH, CRP, D-dimer level during the
hospital stay, and admission risk of mortality categorized as
extreme were more likely to die. Moreover, patients who received HCQ, were on invasive mechanical ventilation, or received epoprostenol sodium during their hospital stay were
more likely to die.
COVID-19 has been challenging in many aspects and its
mortality has been significantly higher compared to other patients with viral pneumonia who get admitted to the ICUs [6].
This may be either due to a more deadly disease process or a
sudden influx of a higher number of patients in the ICUs that
were not well equipped to handle the influx. However, mortality from COVID-19 has been consistent across the globe with
a trend towards a reduction in mortality with time. A metaanalysis of 24 studies comprising ICU patients revealed an
overall mortality rate of 41% between the months of March
to May 2020. It reduced from 50% in March 2020 to 40% at
the end of May 2020 [7]. These results are consistent with our
results demonstrating a reduction in mortality over time. A ret-

rospective cohort study from Wuhan, China, early in the disease course reported ICU mortality up to 90% in the patients
who received mechanical ventilation during the hospital stay
[8]. Our results were similar in that the overall mortality rate
was 79% in the ICU patients who were intubated compared to
patients who were not.
The most notable finding from our study is that mortality
significantly improved from the beginning of March to August. Even after adjusting for geographical location and metaregression by month, the publications revealed that mortality
had significantly decreased all around the globe over time,
starting from China later followed by reports from Europe and
North America [7]. Similarly, Intensive Care National Audit
& Research Centre (ICNARC) reports reveal a peak at 52%
in April, and a trend towards a reduction in mortality in the
following months [9]. Despite variation in admission criteria
to the ICU and difference in relative proportions of patients
receiving non-invasive versus invasive mechanical ventilation,
with non-invasive mechanical ventilation being more prevalent in Asia than Europe and America, ICU mortality did not
differ significantly across the continents. Similarly, there was
a difference in the proportion of use of anti-viral drugs, immunomodulatory treatments and corticosteroids such as HCQ use
more prevalent in Asia than Europe and North America, but
the reduction in mortality over time has been uniform all over
the world [9, 10].
The reasons for this reduction in mortality over time are
likely multifactorial. Increased awareness with growing medical literature might have led to a reduction in mortality over
time. Earlier studies were based on small patient populations
and may have overestimated mortality. Another factor cited by
public health officials contributing to a reduction in mortality
is the shift in demographics towards the younger population
making up the bulk of new infections [11]. An observational
study conducted by researchers at the University of Detroit,
Michigan compared the viral load of patients using the RTPCR who were hospitalized between April and June 2020.
They noticed a significant reduction in the “high viral load
category” from 25.5% in the first week of study to virtually
zero percent in the sixth week [12]. This downward trend in
initial viral load may reflect a reduction in the severity of the
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Table 3. ICU Interventions, Peak Laboratory Values and Outcomes in COVID-19 Patients
Interventions

All (n)

Alive n (%)

Died n (%)

P value

N

1,204

734 (61)

470 (39)

< 0.05

Mechanical ventilation

713

340 (46)

373 (79)

< 0.05

7 ± 13

7±9

0.44

  Duration
BiPAP

399

  Duration
ECMO

27

  Duration

212 (29)

187 (40)

< 0.05

1±3

1±3

0.12

16 (2%)

11 (2)

0.85

1 ± 0.1

1 ± 0.15

0.85

Odds ratio
0.22 (0.12 - 0.29)
0.62 (0.48 - 0.79)
0.93 (0.43 - 2.01)

Nitric oxide

2

1 (0.1)

1 (0.2)

0.75

0.64 (0.40 - 10.25)

HFNC

573

370 (50)

203 (43)

< 0.05

1.33 (1.05 - 1.68)

Flolan

97

26 (3.5)

71 (15)

< 0.05

0.20 (0.13 - 0.32)

476

265 (56)

211 (44)

< 0.05

1.44 (1.13 - 1.82)

2±3

2±3

0.17

162 (60)

110 (40)

0.64

0.3 ± 0.6

0.3 ± 0.6

0.29

105 (65)

57 (35)

0.32

1±2

1±2

0.29

357 (59)

245 (41)

0.26

4±6

4±6

0.84

Medications
  HCQ
    Duration
  TCZ

272

    Duration
  Remdesivir

162

    Duration
  Steroids

602

    Duration

0.93 (0.70 - 1.22)
1.21 (0.86 - 1.71)
0.87 (0.69 - 1.09)

Laboratory values
  D-dimer peak

5,912

4,483

7,342

< 0.05

  Ferritin peak

3,942

1,953

5,931

< 0.05

  LDH peak

782

567

998

< 0.05

  CRP peak

22

20

24

< 0.05

  ESR peak

65

68

62

0.46

136

11 (2)

125 (26)

< 0.05

18 ± 16

12 ± 10

< 0.05

9 ± 12

8±9

0.08

Outcomes
  Comfort care
  Hospital LOS
  ICU LOS
Discharge location

0.04 (0.02 - 0.07)

716

  Inpatient rehabilitation

295 (42)

  SNF

212 (30)

  Home/NH

137 (19)

  Hospice

56 (8)

  AMA

8 (1)

ICU: intensive care unit; BiPAP: bilevel positive airway pressure; ECMO: extracorporeal membrane oxygenation; HFNC: high-flow nasal cannula;
HCQ: hydroxychloroquine; TCZ: tocilizumab; LOS: length of stay; LDH: lactate dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SNF: skilled nursing facility; NH: nursing home; AMA: against medical advice.

pandemic suggesting that viral load may serve as a marker to
assess the progress of the pandemic. Lastly, an increase in the
experience that health care providers obtained throughout the
pandemic, the advancement in research through various clinical trials that have standardized various therapies despite not
finding a cure and protocol improvements among institutions
188

over time are some of the unmeasurable factors that may have
contributed to this reduction in mortality over time.
Several limitations should be considered while interpreting the results of our study. A causal relationship could not be
established due to the retrospective and non-randomized nature of the study. This study includes patients from 14 differ-
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ent hospitals of Jefferson Enterprise and there were unmeasurable variations in approach to patient care among all the
hospitals. The impact of variations in ICU admission criteria,
differences in the expertise of ICU staff, threshold for starting invasive mechanical ventilation and the initiation of several adjunctive therapies at the treating physician’s discretion
could not be determined. We chose laboratory values on day 1
of admission to the ICU, day 10 into ICU stay and peak values
throughout ICU stay because the average duration of any therapy for COVID-19 was less than 10 days. Given the variable
frequency of laboratory specimen collection, we cannot ascertain if these values represented pre and post-treatment values accurately in all cases. Lastly, our study was not designed
to evaluate the contribution of underlying comorbidities to
COVID-19 mortality, nor the potential adverse effects of adjunctive interventions. Many questions remain unanswered;
however, by adjusting the adult patients with the confirmed
disease, we believe our population is representative of the
real-world cohort. Our current COVID-19 treatment practices
mimic other hospital systems, and we believe these results to
be generalizable.
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Conclusions
Our experience with critically ill COVID-19 patients showed
an overall mortality lower than previous reports. More importantly, there was a significant improvement in mortality rates
over time. However, contributing factors largely remain unknown. We believe that improving our understanding of COVID-19 pathophysiology, standardizing management protocols
based on continually evolving data and a decreasing viral load
over time are important factors that may have improved outcomes in COVID-19 patients admitted to the ICU. Research is
needed to further elucidate the factors contributing to mortality
in critically ill COVID-19 patients.
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